A5067271629- Child Nutrition and Water Access
- Child Nutrition and Feeding Issues
- Food Security and Health in Diverse Populations
- Poverty, Education, and Child Welfare
- Obesity, Physical Activity, Diet
Université de Bordeaux
2019-2025
Inserm
2019-2025
Bordeaux Population Health
2019-2025
Institut de Recherche pour le Développement
2020-2024
Abstract The Optimising treatment for acute MAlnutrition (OptiMA) strategy trains mothers to use mid upper arm circumference (MUAC) bracelets screening and targets children with MUAC < 125 mm or oedema one therapeutic food at a gradually reduced dose. This study seeks determine whether OptiMA conforms SPHERE standards (recovery rate > 75 %). A single-arm proof-of-concept trial was conducted in 2017 Yako district, Burkina Faso including aged 6–59 months outpatient health centres oedema....
Global access to acute malnutrition treatment is low. Different programmes using different nutritional products manage cases of severe and moderate separately. We aimed assess whether integrating into one programme, a single product reducing the dose as child improves, could achieve similar or higher individual efficacy, increase coverage, minimise costs compared with current programmes.We conducted an open-label, non-inferiority, randomised controlled trial in Democratic Republic Congo....
Children who receive therapeutic feeding for wasting treatment but do not reach the anthropometric definitions of recovery (usually within 12–16 weeks) are categorised as ‘non-responders’ and considered failures. We conducted a pooled analysis to explore growth trajectories non-responders appropriateness definition ‘non-response’. 14 studies children aged 6–59 months receiving wasting. included classified by their recovered or non-responders. Observing data non-responders’ mid-upper arm...
Current standard management of severe acute malnutrition uses ready-to-use therapeutic food (RUTF) at a single weight-based calculation resulting in an increasing amount RUTF provided to the family as child's weight increases during recovery. Using gradually reduced dosage child recovers could reduce costs while achieving similar growth response.We conducted open-label, non-inferiority, randomised controlled trial Democratic Republic Congo. Children aged 6-59 months with mid-upper-arm...
Abstract Background Simplified approaches of acute malnutrition (AM) treatment have been conducted over the past 5 years intending to unify processes and increase coverage among children aged 6 59 months without medical complication. The Optimsing for Acute Malnutrition (OptiMA) Combined Protocol Study (ComPAS) are mid-upper arm circumference (MUAC)-based treating with MUAC < 125 mm or oedema one sole product—ready-to-use therapeutic food—at a gradually tapered doses. This trial aims...
Globally, access to treatment for severe and moderate acute malnutrition is very low, in part because different protocols products are used separate programs. New approaches, defining (AM) as mid-upper arm circumference (MUAC) < 125 mm or oedema, being investigated compare effectiveness current Optimizing Malnutrition (OptiMA) one such strategy that treats AM with product - ready-to-use therapeutic food, RUTF at reduced dosage the child improves.This study aimed determine whether OptiMA...
Background In the treatment of acute malnutrition (AM), non-response is considered a failure for not meeting recovery criteria within therapeutic window 12–16 weeks, but this category children misunderstood. As current research emphasizes ways to simplify and optimize protocols, emerges as new issue enhance program efficiency. Methods A prospective cohort study was conducted from 2019 2020 at two health centres in Mirriah, Niger among aged 6–59 months with uncomplicated AM treated under...
Introduction Acute malnutrition (AM) is a continuum condition, arbitrarily divided into moderate and severe AM (SAM) categories, funded managed in separate programmes under different protocols. Optimising acute MAlnutrition (OptiMA) treatment aims to simplify optimise management by treating children with mid-upper arm circumference (MUAC) <125 mm or oedema one product—ready-to-use therapeutic food—at gradually tapered dose. Our main objective was compare the OptiMA strategy standard...
Abstract Acute malnutrition (AM) causes large loss of life and disability in children Africa. Researchers are testing innovative approaches to increase the efficiency treatment programs This paper presents results a cost-effectiveness analysis one such program Democratic Republic Congo (DRC) based on secondary randomized controlled trial Optimizing Treatment for Malnutrition (OptiMA), conducted DRC 2018–20. A total 896 aged 6–59 months with mid-upper arm circumference (MUAC) &lt;125 mm...
Background: Current standard management of severe acute malnutrition uses ready-to-use therapeutic food (RUTF) at an increasing dosage as the child’s weight increases during recovery. Using RUTF a gradually reduced child recovers could optimise costs while achieving similar growth response.Methods: We conducted open-label, non-inferiority, randomised controlled trial in Democratic Republic Congo. Children aged 6-59 months with mid-upper arm circumference (MUAC) less than 115 mm or...
The main objective was to compare the OptiMA strategy- ie.supplementing with ready-to-use therapeutic food at a gradually reduced doses- current national standard protocol. This non-inferiority, individually randomised controlled clinical trial conducted in Democratic Republic of Congo. Children 6–59 months MUAC < 125 mm or weight-for-height Zscore< −3 oedema and without medical complication were randomized either arm followed for 6 months. outcome binary composite indicator 6-months post...
The main secondary objective of OptiMA-DRC trial was to compare the OptiMA strategy, ie.supplementing with one product, ready-to-use therapeutic food at a gradually reduced doses, current national nutritionnal standard protocol in children uncomplicated severe acute malnutrition (SAM) inclusion (MUAC < 115 mm or WHZ< −3 oedema) both arms. This non-inferiority, individually randomised controlled clinical conducted Kasai province, Democratic Republic Congo (DRC) between July 2019 and 2020....